In a patient after return of spontaneous circulation from cardiac arrest, should vasopressin be used as the first-line vasopressor for post‑arrest hypotensive shock?

Vasopressin Should NOT Be Used as First-Line Post-Cardiac Arrest

There is insufficient evidence to recommend vasopressin as a first-line vasopressor after cardiac arrest, and norepinephrine is the preferred agent when hypotension requires treatment. 1, 2

Guideline Recommendations

The most recent 2025 American Heart Association guidelines explicitly state that "there is insufficient evidence to recommend a specific vasopressor to treat low blood pressure in adult patients after cardiac arrest" 1. However, this does not mean all vasopressors are equal.

The 2025 European Resuscitation Council guidelines provide more specific direction: norepinephrine is recommended as the first-line vasopressor for managing hypotension in post-cardiac arrest patients 2. This recommendation is based on:

• Norepinephrine being the most commonly used first-line vasopressor in distributive shock
• Good tolerability in post-ROSC patients without clinically significant arrhythmias
• Its established role in managing hypotensive complications like cardiogenic shock, acute coronary syndromes, and sepsis

Why Not Vasopressin?

Limited Evidence Base

The FDA label for vasopressin indicates it has been studied in septic shock and post-cardiotomy vasodilatory shock 3, but cardiac arrest is not an FDA-approved indication. The clinical studies section makes no mention of post-cardiac arrest use.

No Superiority Over Standard Agents

While vasopressin has been studied during cardiac arrest resuscitation itself (during CPR), the evidence for post-ROSC use is essentially non-existent. The systematic reviews examining vasopressin focus on its use during cardiac arrest, not after ROSC is achieved 4.

Practical Considerations

The European guidelines note that in settings where norepinephrine is not available (e.g., pre-hospital), epinephrine infusion may be an accepted approach 2. Vasopressin is not mentioned as an alternative, suggesting it has no established role in this setting.

Clinical Algorithm for Post-Arrest Hypotension

Target: Maintain MAP ≥65 mmHg 1

First-line vasopressor: Norepinephrine 2

• Can be safely infused peripherally if needed (dilute to 8-40 µg/mL) 2
• Well-tolerated without significant arrhythmias even at higher doses 2

If norepinephrine unavailable: Epinephrine infusion 2

• Note: Observational data suggest epinephrine may be associated with higher rates of re-arrest compared to norepinephrine 5, 6, though this may reflect confounding by indication

Avoid: Dopamine combinations (associated with worse outcomes) 2

Common Pitfalls

1. Don't confuse intra-arrest with post-arrest management: Vasopressin has been studied as an alternative to epinephrine during CPR, but this is a completely different clinical scenario than post-ROSC hypotension

2. Vasopressin is not interchangeable with other vasopressors: It has a distinct mechanism (V1 receptor-mediated vasoconstriction) and lacks the evidence base for post-cardiac arrest use 3

3. Availability matters: In pre-hospital settings, epinephrine is more readily available than norepinephrine and is acceptable when norepinephrine cannot be obtained 2

Bottom Line

Use norepinephrine as your first-line vasopressor for post-cardiac arrest hypotension. Vasopressin has no established role in this setting and should not be used. If norepinephrine is unavailable, use epinephrine. The goal is maintaining MAP ≥65 mmHg to optimize outcomes 1, 2.